key: cord-0751156-58guj2i4 authors: Kara Polat, Asude; Oguz Topal, Ilteris; Karadag, Ayse Serap; Aksoy, Hasan; Koku Aksu, Ayse Esra; Ozkur, Ezgi; Ozkok Akbulut, Tugba; Topaloglu Demir, Filiz; Engin, Burhan; Uzuncakmak, Tugba Kevser; Kıvanc Altunay, Ilknur title: The impact of COVID‐19 in patients with psoriasis: A multicenter study in Istanbul date: 2020-12-30 journal: Dermatol Ther DOI: 10.1111/dth.14691 sha: 1716670545b5371a11b4de7ecd7949182c805377 doc_id: 751156 cord_uid: 58guj2i4 There is widespread concern about treatment of psoriasis in COVID‐19 pandemic. We aimed to evaluate the epidemiological data, clinical characteristics, treatment features of the psoriasis patients during the pandemic period. We conducted a study in dermatology clinics of seven different tertiary centers. All adult psoriasis patients who were followed up between 11 March 2020 and 28 June 2020, were phone called or questioned in their visit to their follow‐up clinics. A semistructured questionnaire was applied and patients' demographics and disease characteristics were recorded. Of 1322 patients, 52.4% were male, and 47.6% were female. According to the questionnaire responses, 964 (72.9%) of these patients could not communicate with their physician during this period, remained 358 (27.1%) patients contacted the physician by phone, email, or hospital visit. From the patients diagnosed as probable/confirmed COVID‐19, 14 were female, and 9 were male. Nine of 23 (39.1%) patients were using biologic treatment. There was no statistically significant difference in terms of hospitalization from COVID‐19 between the patients using biologics (n = 9) and those who did not (n = 14) (P = 1.00). No mortality was observed among them. Obesity, smoking, age, and accompanying psoriatic arthritis were not among the risk factors affecting the frequency of COVID‐19. We only encountered an increased risk in diabetic patients. Also, an exacerbation of psoriasis was observed with the infection. No difference was found in patients with psoriasis in terms of COVID‐19 infection in patients who use biologics and those who don't. Patients who met clinical criteria and had contact with probable or confirmed cases; and/or a suspect case with chest imaging showing findings suggestive of COVID-19 disease (multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution in chest computerized tomography) were considered as probable COVID-19. 4 Older age, cardiovascular disease, diabetes, chronic respiratory disease, hypertension and cancer were defined as risk factors for increased risk of death. 5 Psoriasis is a chronic inflammatory disease with a worldwide frequency of approximately 2% to 3%. Elderly psoriasis patients and/or patients using conventional immunosuppressive regimens and biologic agents are at higher risk for infectious diseases. But despite some reports about psoriasis and COVID-19, there is uncertainty concerning outcomes of infection in patients with psoriasis or those treated with immunosuppressive therapies. 6, 7 The course of COVID-19 also varies between countries, so it is important for countries to create their own data for this barely understood disease. The main aim of the study was to evaluate epidemiological data for patients with psoriasis during the pandemic period in Istanbul. The secondary aim was to evaluate clinical characteristics of psoriasis patients with COVID-19 and compare rates for patients who received or did not receive immunosuppressive or biological therapies. We conducted a study in dermatology clinics of seven different tertiary centers. All adult psoriasis patients followed up between 11 March 2020 and 28 June 2020 were phoned or questioned in visits to follow-up clinics. A semistructured questionnaire was developed and administered to patients giving verbal consent. Demographics and disease characteristics were recorded from patients' medical files. Patients' demographic features (age, gender, body mass index [BMI] , smoking, alcohol use) and disease characteristics (type of psoriasis, duration of disease, comorbidities, psoriasis treatments) were recorded. During the COVID-19 period, patients answered questions about whether they communicated with their doctors, how they continued treatment and whether they were diagnosed with COVID-19. The data (diagnosis methods, symptoms, hospitalization duration, treatment for COVID-19, prognosis) of patients who said they were diagnosed with COVID-19 was recorded from their medical records. If patients were working during this period, they were also asked about compliance with isolation rules and whether someone in contact with them had been diagnosed with COVID-19. In our study, the diagnosis of COVID-19 was determined as probable/confirmed COVID-19 as defined by WHO. 4 We compared our data with the data of the Ministry of Health. In the descriptive statistics, the mean, SD, median lowest and highest, frequency and ratio values were used. The distribution of variables was measured with the Kolmogorov Smirnov test. Mann-Whitney's test was used to analyze the independent quantitative data. The chisquare test was used to analyze the independent qualitative data, and a Fischer test was used when chi-square test conditions were not met. The SPSS 26.0 program was used in the analyses. Our study enrolled 1322 patients from seven different centers; 52% (n = 693) were male and 47.6% female. The mean age was 47.0 ± 14.4 years. In our study, the age, gender, weight, height, BMI value, BMI distribution, smoking rate, smoking duration, alcohol use rate and working rate in this period were not significantly different among COVID-19 (−) and (+) groups (P > .05). In the COVID-19 (+) group, the DM rate was significantly higher than in the COVID-19 (−) group (P = .024). Rates of obesity, HT, lung disease, renal disease, liver disease, cancer and psychiatric disease did not show a statistically significant difference in the COVID-19 (−) and (+) groups (P > .05). Patient characteristics are included in Table 1 No patient stayed in the intensive care unit (ICU), and death due to the disease was not observed. Fifty-five per cent of the patients (n = 15) diagnosed with COVID-19 experienced exacerbation of psoriasis after the disease. Eleven (47.8%) of 23 patients had a history of contact with COVID-19 positive people. In the COVID-19 (+) group, the history of contacting someone with COVID-19 was statistically significantly higher than in the COVID-19 (−) group (P = .000). Of patients diagnosed with probable/confirmed COVID-19, 14 were female, and 9 were male. Nine of the 23 (39.1%) patients used biologic treatments. There was no statistically significant difference in terms of hospitalization from COVID-19 between patients using biologics (n = 9) and those not using them (n = 14) (P = 1.00). For hospitalization, there was no statistically significant difference between patients who used immunosuppressives (n = 12) and those who did not (n = 11) (P = .54). The percentage of patients with COVID-19 did not differ between groups using biologics or immunosuppressives (Table 4 ). According to the Nomenclature of Territorial Units for Statistics Our study was similar to previous studies. We found the percentage of patients with COVID-19 did not differ between those receiving biologic/immunosuppressive treatments and those who were not. There was no statistically significant difference in terms of hospitalization between patients using biologics (n = 9) and those who were not (n = 14) (P = 1.00); nor was there any statistically significant difference between the percentage of patients using immunosuppressives (n = 12) and those who were not (n = 11) (P = 0.54). No patient stayed in the ICU, and no deaths occurred due to COVID-19. According to our data, the frequency of COVID-19 does not increase in patients using immunosuppressants, including those receiving biological therapy with a diagnosis of psoriasis. Although the number of patients diagnosed with COVID-19 is not very high, the course of COVID-19 does not change with immunomodulating or immunosuppressive therapy. Interestingly, obesity, smoking, age and accompanying psoriatic arthritis were not among the factors affecting the frequency of COVID-19. We only encountered an increased risk in diabetic patients. We also found no difference between immunosuppressive treatments or biological agents in terms of susceptibility to COVID-19. However, an exacerbation of psoriasis was observed with the infection, which may be related to cessation of psoriasis treatments. Grading on tomographic evaluation could be important in evaluating disease prognosis. Even though our study was multicentered, our data were limited to Istanbul. A similar study could be conducted with clinics located in different centers countrywide. Our study found no difference in patients with psoriasis in terms of getting COVID-19 while using biologics. Our study is the first multicentered study for Turkey on COVID-19 in patients with psoriasis. In this respect, it is important both for Turkey and for international data. World Health Organization. Novel Coronavirus (2019-nCoV) SITUA-TION REPORT-1 COVID-19 Situation report World Health Organization WHO COVID-19 Case definition Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Comment on ''COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action COVID-19 and psoriasis: biologic treatment and challenges Biologic therapy for psoriasis during the covid-19 outbreak is not a choice Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits Covid-19 infection in psoriasis patients treated with cyclosporin Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the northern Italy experience COVID-19 and biologics for psoriasis: a high-epidemic area experience-Bergamo Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul The authors declare no conflicts of interest.